4.5 Article

Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Immunology

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

Bertrand Allard et al.

IMMUNOLOGICAL REVIEWS (2017)

Article Pharmacology & Pharmacy

Immunosuppressive activities of adenosine in cancer

Bertrand Allard et al.

CURRENT OPINION IN PHARMACOLOGY (2016)

Review Immunology

A Metabolic immune Checkpoint: Adenosine in Tumor Microenvironment

Akio Ohta

FRONTIERS IN IMMUNOLOGY (2016)

Article Oncology

Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor

Deepak Mittal et al.

CANCER RESEARCH (2014)

Article Pharmacology & Pharmacy

Istradefylline: First Global Approval

Rosselle Dungo et al.

Article Multidisciplinary Sciences

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

Sherene Loi et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Article Multidisciplinary Sciences

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors

Paul A. Beavis et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Review Biochemistry & Molecular Biology

Extracellular adenosine triphosphate and adenosine in cancer

J. Stagg et al.

ONCOGENE (2010)